Human Microbiome Market (Indication - Gastrointestinal and Metabolic Disorders, Women’s Health, and Cancer; Technology - 16s rRNA Sequencing and Metagenomic Sequencing; Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Women’s Health, and Skin Disorders) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2024
Albany, NY -- (SBWIRE) -- 07/18/2017 -- Microbiome diagnostics and microbiome therapeutics are the two prominent sections of the global human microbiome market. Currently, the market is in the budding phase, with most of the therapies still being in preclinical or clinical (phase I or phase II) stage. The diagnosis technology is also in the development phase and the leading companies have begun to allocate funds for the research and development and the management of clinical studies for their innovative class of therapies. All these factors are likely to propel this market significantly over the next few years. The human microbiome therapeutics market is likely to report a CAGR of 9.20% during the period of 2020 to 2024, whereas the market for human microbiome diagnostics is anticipated to rise at an 8.60% CAGR between 2018 and 2024.
North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America are the key regional markets for human microbiome across the world. Thanks to the presence of a state-of-art medical and healthcare industry and early adoption of technology, North America has occupied the top position in the global market. Researchers expect that the rising number of venture-capital funded start-ups and the increasing investments by leading players for research and development of drug http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3999 s will support the North America market for human microbiome over the forthcoming years, ensuring its dominance. The human microbiome therapeutics market in North America is anticipated to report a rise at a CAGR of 9.10% between 2020 and 2024 while the region's human microbiome diagnostics market will progress at an 8.80% CAGR from 2018 to 2024.
Inquire for a Sample Copy of Report - http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3999
Europe, which acquired the second position in the global human microbiome market, is projected to maintain its position over the years to come. The U.K. and France have emerged as the key domestic markets for human microbiome in Europe. The high investments by companies in this domain are expected to boost both these domestic markets in the next few years. Apart from this, countries, such as Sweden and the Netherlands, are also anticipated to contribute well to the Europe market for human microbiome market in the near future.
On the basis of technology, the global market for human microbiome is classified into 16s rRNA sequencing and metagenomic sequencing. Both the technology are equally popular platforms for detection in the microbiome-based diagnostics. However, the metagenomic sequencing segment is likely to surpass the 16s rRNA segment over the next few years, albeit by a small margin, as a large number of companies are opting for the diagnosis of a more comprehensive microbiome profile.
At the forefront of the global market for human microbiome are Vedanta Biosciences, Synthetic Biologics Inc., Seres Therapeutics, Second Genome, uBiome Inc., Rebiotix Inc., Osel Inc., MicroBiome Therapeutics LLC., Metabiomics Corp., Enterome Biosciences SA, and AO Biome LLC. Some of the other prominent participants in this market are Metabogen AB, Becton Dickinson & Co., Evelo Biosciences, ARTPred, MaaT Pharma, Blue Turtle Bio Technologies, Axial Therapeutics, Whole Biome, 4D Pharma, Symbiotix Therapies, Phi Therapeutics, Synlogic, and Biospherex LLC.
Read Report with Complete TOC - http://www.transparencymarketresearch.com/human-microbiome-market.html